-
公开(公告)号：EP2079729A1
公开(公告)日：2009-07-22
申请号：EP07844851.1
申请日：2007-11-02
申请人： IRM LLC , NOVARTIS AG
发明人： CHIANELLI, Donatella , LI, Xiaolin , LIU, Xiaodong , LOREN, Jon , MOLTENI, Valentina , NABAKKA, Juliet , REVESZ, Laszlo , PEREZ, Lawrence B. , BROOKS, Clinton , WRONA, Wojciech , MANLEY, Paul W. , BREITENSTEIN, Werner
IPC分类号： C07D401/14 , C07D403/12 , C07D405/14 , C07D407/14 , C07D413/14 , C07D417/14 , C07D471/04 , A61K31/506 , A61P33/06 , A61P25/00 , A61P35/00
CPC分类号： C07D401/14 , C07D401/04 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14
摘要： The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to beat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of c-kit, PDGFRα and PDGFRβ kinases. Formula (I).
摘要翻译： 本发明提供了一类新化合物，包含此类化合物的药物组合物以及使用这些化合物来击败或预防与异常或失调的激酶活性相关的疾病或病症，特别是涉及c-kit，PDGFRα和PDGFRα异常活化的疾病或病症 PDGFRβ激酶。 公式（I）。
-
公开(公告)号：EP1735307A1
公开(公告)日：2006-12-27
申请号：EP05716547.4
申请日：2005-04-06
申请人： Novartis AG , Novartis Pharma GmbH
发明人： PALERMO, Mark, G. , SHARMA, Sushil, Kumar , STRAUB, Christopher , WANG, Run-Ming , ZAWEL, Leigh , ZHANG, Yanlin , CHEN, Zhuoliang , WANG, Yaping , YANG, Fan , WRONA, Wojciech , LIU, Gang , CHAREST, Mark, G. , HE, Feng
IPC分类号： C07D471/04 , C07D207/09 , C07D207/06 , C07D403/04 , C07D207/08 , C07D487/04 , C07D401/04 , C07D401/12 , C07D413/04 , C07D413/14 , C07D417/04 , C07D409/12 , C07D403/12 , C07D405/12 , A61K31/437
CPC分类号： C07D207/16 , C07D207/06 , C07D207/08 , C07D207/09 , C07D401/04 , C07D401/12 , C07D403/04 , C07D403/06 , C07D403/12 , C07D405/10 , C07D405/12 , C07D409/12 , C07D413/04 , C07D413/14 , C07D417/04 , C07D471/04 , C07D487/04
摘要： Novel compounds that inhibit the binding of the Smac protein to Inhibitor of Apoptosis Proteins (IAPs) of the formula (I).
-
公开(公告)号：EP1735307B1
公开(公告)日：2012-08-29
申请号：EP05716547.4
申请日：2005-04-06
申请人： Novartis AG
发明人： PALERMO, Mark, G. , SHARMA, Sushil, Kumar , STRAUB, Christopher , WANG, Run-Ming , ZAWEL, Leigh , ZHANG, Yanlin , CHEN, Zhuoliang , WANG, Yaping , YANG, Fan , WRONA, Wojciech , LIU, Gang , CHAREST, Mark, G. , HE, Feng
IPC分类号： C07D207/16 , C07D207/09 , C07D207/06 , C07D403/04 , C07D401/04 , C07D401/12 , C07D413/14 , C07D417/04 , C07D403/12 , C07D405/12 , C07D413/04
CPC分类号： C07D207/16 , C07D207/06 , C07D207/08 , C07D207/09 , C07D401/04 , C07D401/12 , C07D403/04 , C07D403/06 , C07D403/12 , C07D405/10 , C07D405/12 , C07D409/12 , C07D413/04 , C07D413/14 , C07D417/04 , C07D471/04 , C07D487/04
-
公开(公告)号：EP2331547A1
公开(公告)日：2011-06-15
申请号：EP09782051.8
申请日：2009-08-20
发明人： BESONG, Gilbert , BRAIN, Christopher Thomas , BROOKS, Clinton A. , CONGREVE, Miles Stuart , DAGOSTIN, Claudio , HE, Guo , HOU, Ying , HOWARD, Steven , LI, Yue , LU, Yipin , MORTENSON, Paul , SMITH, Troy , SUNG, Moo , WOODHEAD, Steven , WRONA, Wojciech
IPC分类号： C07D487/04 , A61K31/519 , A61P35/00
CPC分类号： C07D487/04 , A61K31/519 , C07D487/08
摘要： The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein.
摘要翻译： 所公开的化合物涉及蛋白激酶相关病症的治疗和治疗。 还需要用于治疗或预防或改善癌症，移植排斥和自身免疫疾病的一种或多种症状的化合物。 此外，需要使用本文提供的化合物来调节蛋白激酶例如CDK1，CDK2，CDK4，CDK5，CDK6，CDK7，CDK8和CDK9的活性的方法。
-
公开(公告)号：EP2331547B1
公开(公告)日：2014-07-30
申请号：EP09782051.8
申请日：2009-08-20
发明人： BESONG, Gilbert , BRAIN, Christopher Thomas , BROOKS, Clinton A. , CONGREVE, Miles Stuart , DAGOSTIN, Claudio , HE, Guo , HOU, Ying , HOWARD, Steven , LI, Yue , LU, Yipin , MORTENSON, Paul , SMITH, Troy , SUNG, Moo , WOODHEAD, Steven , WRONA, Wojciech , LAGU, Bharat
IPC分类号： C07D487/04 , A61K31/519 , A61P35/00
CPC分类号： C07D487/04 , A61K31/519 , C07D487/08
摘要： The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein.
-
-
-
-
搜索结果
5 条记录 (耗时 0.016 秒)
